BSEM (BioStem Technologies) Debt-to-Asset : 0.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSEM BioStem Technologies Inc BSEM
37 GF Score
Price $4.40
! 6 Warning Signs
View Full Analysis

What is BioStem Technologies Debt-to-Asset?

BioStem Technologies BSEM -6.88% 37 Debt-to-Asset is 0.03 as of Jun. 2026. GuruFocus rates BSEM with a GF Score™ of 37/100. The stock has 6 warning signs investors should review.

BioStem Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.22 Mil. BioStem Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. BioStem Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $48.82 Mil. BioStem Technologies's debt to asset for the quarter that ended in Jun. 2026 was 0.03.

BioStem Technologies  (NAS:BSEM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BioStem Technologies Debt-to-Asset Related Terms

BioStem Technologies Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Debt-to-Asset Chart

BioStem Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.84 1.46 0.33 0.08 0.07

BioStem Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.05 0.07 0.06 0.03

BSEM vs IBIO, CSBR, PLRX: Debt-to-Asset Comparison

For the Biotechnology subindustry, BioStem Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioStem Technologies Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Debt-to-Asset falls into.


BSEM
37GF Score
BioStem Technologies Inc BSEM
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioStem Technologies's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.225768 + 0.105262) / 50.195754
=0.07

BioStem Technologies's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.222471 + 0.001355) / 48.818296
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.03 mean?
BioStem Technologies (BSEM) has a Debt-to-Asset of 0.03 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' Debt-to-Asset too high?
BioStem Technologies' current Debt-to-Asset is 0.03. Overall, BioStem Technologies has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Debt-to-Asset compare to IBIO and CSBR?
BioStem Technologies' Debt-to-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Debt-to-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current Debt-to-Asset of 0.03. The current Debt-to-Asset is 0.03. BioStem Technologies' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Debt-to-Asset is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioStem Technologies Business Description

Other Exchanges 0JQ:Germany
Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
37GF Score

Get the complete analysis for BSEM

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.40
Price